Table 5.

Results of economic assessment. Number of administrations of sugammadex over which at least one death must be prevented for sugammadex to appear cost-effective. CICV, ‘can't intubate, can't ventilate’. *Since no reduction in recovery time is realized, the location of any possible reduction is irrelevant. ^†Short procedures (<60 min) or long procedures (>60 min) which require profound block throughout. ^‡Long procedures (>60 min) which do not require profound block throughout

Location of any reduction in recovery time	Operating theatre						Recovery room
Age of patient	20 yr			60 yr			20 yr			60 yr
Probability of CICV event (%)	0	0.5	1	0	0.5	1	0	0.5	1	0	0.5	1
Very short procedures*	3678	3643	3609	1979	1960	1942	3678	3643	3609	1979	1960	1942
Short procedures†	Sugammadex cost-effective without mortality benefit						4696	4633	4571	2527	2493	2460
Long procedures‡	Sugammadex cost-effective without mortality benefit						8790	8535	8295	4730	4593	4463